Case Study

68Gallium-prostate-specific membrane antigen ligand positron-emission tomography or computed tomography in biochemical failure after radical prostatectomy: A case report

Irene A. Chidothe, David B. Anderson
South African Journal of Oncology | Vol 1 | a16 | DOI: https://doi.org/10.4102/sajo.v1i0.16 | © 2017 Irene A. Chidothe, David B. Anderson | This work is licensed under CC Attribution 4.0
Submitted: 02 March 2017 | Published: 28 April 2017

About the author(s)

Irene A. Chidothe, Department of Radiation Oncology, Faculty of Healthy Sciences, University of Cape Town, Groote Schuur Hospital, South Africa
David B. Anderson, Department of Radiation Oncology, Faculty of Healthy Sciences, University of Cape Town, Groote Schuur Hospital, South Africa


Share this article

Bookmark and Share

Abstract

Biochemical failure after radical treatment for prostate cancer occurs in up to 30% – 50% of cases. Localisation of clinical disease is challenging because clinical symptoms often manifest long after the initial rise in prostate-specific antigen. The detection rates of imaging modalities such as contrasted computed tomography (CT), bone scan, magnetic resonance imaging and choline positron-emission tomography (PET) or CT, are limited. Prostate-specific membrane antigen (PSMA) ligand PET or CT is a novel imaging modality under investigation for various diagnostic and therapeutic indications in the management of prostate cancer. We present a case report illustrating how 68Gallium-PSMA ligand PET or CT was used to guide management in a patient presenting with biochemical failure after radical prostatectomy.

Keywords

prostate cancer; biochemical failure; 68Ga-PSMA PET/CT

Metrics

Total abstract views: 1749
Total article views: 3048


Crossref Citations

No related citations found.